1 Department of Blood Sciences, Leeds General Infirmary, Old Medical School, Leeds, UK.
2 The Department of Medical Physics & Engineering, St. James's University Hospital, Leeds, UK.
Ann Clin Biochem. 2019 Mar;56(2):266-274. doi: 10.1177/0004563218822667. Epub 2019 Feb 21.
Equations to estimate glomerular filtration rate based on serum creatinine are commonly used in cancer patients to assess renal function. However, there is uncertainty regarding which equation is most appropriate for this population and the impact of different creatinine assays.
Measured isotopic glomerular filtration rate results from 120 oncology patients were used to evaluate and compare all four versions of the Wright equation, Cockcroft and Gault, Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration and the Janowitz and Williams formula; using eight different creatinine assays (five Jaffe, three enzymatic).
The enzymatic version of the Wright equation without creatine kinase performed better than the other versions for all eight creatinine assays. However, MDRD and Janowitz and Williams gave the best overall performance in this patient population. Performance was highly dependent on the creatinine assay used, for example, the percentage of results within 30% of the isotopic glomerular filtration rate (P30) ranged from 90.8% to 60.8% for MDRD.
The performance of any equation to estimate glomerular filtration rate is highly dependent on the creatinine assay used. Oncology units should assess the performance of glomerular filtration rate equations using their laboratory creatinine assay to determine whether they can be used safely and effectively in cancer patients.
基于血清肌酐的肾小球滤过率估算方程常用于癌症患者以评估肾功能。然而,对于哪种方程最适合该人群以及不同肌酐检测方法的影响,仍存在不确定性。
使用 120 名肿瘤患者的同位素肾小球滤过率测量结果来评估和比较 Wright 方程的所有四个版本、Cockcroft 和 Gault 方程、改良肾脏病饮食研究(MDRD)方程、慢性肾脏病流行病学合作(CKD-EPI)方程和 Janowitz 和 Williams 公式;使用 8 种不同的肌酐检测方法(5 种 Jaffe 法,3 种酶法)。
对于所有 8 种肌酐检测方法,不包含肌酸激酶的酶法 Wright 方程的表现优于其他版本。然而,在该患者人群中,MDRD 和 Janowitz 和 Williams 给出了最佳的整体表现。性能高度依赖于所使用的肌酐检测方法,例如,MDRD 的 P30(同位素肾小球滤过率的 30%内的结果百分比)范围从 90.8%到 60.8%。
任何估算肾小球滤过率的方程的性能都高度依赖于所使用的肌酐检测方法。肿瘤学单位应使用其实验室的肌酐检测方法评估肾小球滤过率方程的性能,以确定它们是否可以在癌症患者中安全有效地使用。